Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 4/20 | 0.32 |
| ▸ | CTSK | P43235 | 4/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498289 | 1.00 | MEN1 (0.36) | MEN1KMT2ATRPA1EGLN2CYP1A2 | |
| SCHEMBL24717559 | 0.88 | ALDH1A1 (0.36) | MEN1KMT2ACTSSCTSKALDH1A1 | |
| SCHEMBL25051768 | 0.87 | MEN1 (0.36) | MEN1KMT2ATRPA1EGLN2CYP1A2 | |
| SCHEMBL24917988 | 0.86 | MEN1 (0.35) | MEN1KMT2ATRPA1EGLN2CYP1A2 | |
| SCHEMBL25643117 | 0.86 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1NPC1KDM4E | |
| SCHEMBL30015365 | 0.85 | — | — | |
| SCHEMBL30781872 | 0.84 | TRPA1 (0.35) | MEN1KMT2ATRPA1EGLN2CYP1A2 | |
| SCHEMBL23496853 | 0.84 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL29813201 | 0.84 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL27100884 | 0.84 | TRPA1 (0.35) | MEN1KMT2ATRPA1EGLN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029168-A | Methods for preparing KRAS G12C inhibitors | 伊莱利利公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC | 2026-03-26 | — | — | US | disclosed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260034126-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| EP-4640684-A1 | KRAS G12D INHIBITORS AND USES THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-10-29 | — | — | EP | disclosed |
| CN-117820333-A | KRAS G12C inhibitors | 伊莱利利公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-117500799-A | Substituted fused azines as KRAS G12D inhibitors | 伊莱利利公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-114828964-B | KRAS G12C inhibitors | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023196959-A1 | PROCESS FOR MAKING A KRAS G12C INHIBITOR | ELI LILLY AND COMPANY (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023097227-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023018699-A1 | SELECTIVE KRAS INHIBITORS | ERASCA, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| CN-114828964-A | KRAS G12C inhibitors | 伊莱利利公司 | 2022-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034126-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 3241/4885KMT2A 1943/4885TRPA1 4615/4885 |
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | KRAS, NRAS, RASGRP1 | MEN1 434/4885KMT2A 2490/4885TRPA1 3551/4885 |
| US-20260069605-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 971/4885KMT2A 3566/4885TRPA1 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.